ReviewMicroarrays (Basel, Switzerland)2015
Aptamer Microarrays-Current Status and Future Prospects.
Review in Microarrays (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 57 citations in OpenAlex.
- DNA-Based Environmental Remediation: Functional Principles, Material Platforms, and Future Perspectives.Materials (Basel, Switzerland) · 2026Review
- Aptamer-functionalized polydiacetylene biosensor for the detection of three foodborne pathogens.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- Detection of Biomarker Using Aptasensors to Determine the Type of Diabetes.Diagnostics (Basel, Switzerland) · 2023Review
- Recent Progress in Development and Application of DNA, Protein, Peptide, Glycan, Antibody, and Aptamer Microarrays.Biomolecules · 2023Review
- Molecular Targets for Foodborne Pathogenic Bacteria Detection.Pathogens (Basel, Switzerland) · 2023Review
- Enhancement of in vivo targeting properties of ErbB2 aptamer by chemical modification.PloS one · 2023Article
- A Novel ssDNA Aptamer Targeting Carcinoembryonic Antigen: Selection and Characterization.Biology · 2022Article
- Era of Molecular Diagnostics Techniques before and after the COVID-19 Pandemic.Current issues in molecular biology · 2022Review
- Electrochemical Aptasensors Based on Hybrid Metal-Organic Frameworks.Sensors (Basel, Switzerland) · 2020Review
- Article
- Aptamer-Modified Magnetic Beads in Biosensing.Sensors (Basel, Switzerland) · 2018Review
- Current applications of antibody microarrays.Clinical proteomics · 2018Review
- Mapping the affinity landscape of Thrombin-binding aptamers on 2΄F-ANA/DNA chimeric G-Quadruplex microarrays.Nucleic acids research · 2017Article
- Living Cell Microarrays: An Overview of Concepts.Microarrays (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microarray technologies are state of the art in biological research, which requires fast genome, proteome and transcriptome analysis technologies. Often antibodies are applied in protein microarrays as proteomic tools. Since the generation of antibodies against toxic targets or small molecules including organic compounds remains challenging the use of antibodies may be limited in this context. In contrast to this, aptamer microarrays provide alternative techniques to circumvent these limitations. In this article we review the latest developments in aptamer microarray technology. We discuss similarities and differences between DNA and aptamer microarrays and shed light on the post synthesis immobilization of aptamers including corresponding effects on the microarray performance. Finally, we highlight current limitations and future prospects of aptamer microarray technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.